In CASPIAN trial, of 277 patients with evaluable samples, 151 patients were in the durvalumab group, PD-L1 expression was low with 5% expression of ≥1% in tumor cells (TC) and 22% in immune cells (IC). The gene discussed is CD274; the disease is neoplasm.